The regulation of MDM2 oncogene and its impact on human cancers

被引:132
|
作者
Zhao, Yuhan [1 ]
Yu, Haiyang [1 ]
Hu, Wenwei [1 ,2 ]
机构
[1] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA
[2] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, Dept Pharmacol, New Brunswick, NJ 08903 USA
基金
美国国家卫生研究院;
关键词
MDM2; E3 ubiquitin ligase; gene regulation; p53; TUMOR-SUPPRESSOR PATHWAY; P53-MDM2 FEEDBACK LOOP; UBIQUITIN LIGASE ACTIVITY; RIBOSOMAL-PROTEIN L26; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; ACTIVATES P53; MUTANT P53; P53-DEPENDENT MANNER; ONCOPROTEIN MDM2;
D O I
10.1093/abbs/gmt147
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor suppressor p53 plays a central role in preventing tumor formation. The levels and activity of p53 is under tight regulation to ensure its proper function. Murine double minute 2 (MDM2), a p53 target gene, is an E3 ubiquitin ligase. MDM2 is a key negative regulator of p53 protein, and forms an auto-regulatory feedback loop with p53. MDM2 is an oncogene with both p53-dependent and p53-independent oncogenic activities, and often has increased expression levels in a variety of human cancers. MDM2 is highly regulated; the levels and function of MDM2 are regulated at the transcriptional, translational and post-translational levels. This review provides an overview of the regulation of MDM2. Dysregulation of MDM2 impacts significantly upon the p53 functions, and in turn the tumorigenesis. Considering the key role that MDM2 plays in human cancers, a better understanding of the regulation of MDM2 will help us to develop novel and more effective cancer therapeutic strategies to target MDM2 and activate p53 in cells.
引用
收藏
页码:180 / 189
页数:10
相关论文
共 50 条
  • [21] MDM2 oncogene as a target for cancer therapy: An antisense approach
    Wang, H
    Zeng, XF
    Oliver, P
    Le, LP
    Chen, JD
    Chen, LH
    Zhou, WQ
    Agrawal, S
    Zhang, RW
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (04) : 653 - 660
  • [22] Pathobiology of hemophilic synovitis I:: overexpression of mdm2 oncogene
    Hakobyan, N
    Kazarian, T
    Jabbar, AA
    Jabbar, KJ
    Valentino, LA
    BLOOD, 2004, 104 (07) : 2060 - 2064
  • [23] Mdm2 widens its repertoire
    Coutts, Amanda S.
    La Thangue, Nicholas B.
    CELL CYCLE, 2007, 6 (07) : 827 - 829
  • [24] Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms
    Matsumoto, R
    Tada, M
    Nozaki, M
    Zhang, CL
    Sawamura, Y
    Abe, H
    CANCER RESEARCH, 1998, 58 (04) : 609 - 613
  • [25] Regulation of VEGF transcription by MDM2 protoncogene
    Narasimhan, Madhusudhanan
    Rathinavelu, Appu
    CANCER RESEARCH, 2006, 66 (08)
  • [26] A role for the polyproline domain of p53 in its regulation by Mdm2
    Berger, M
    Sionov, RV
    Levine, AJ
    Haupt, Y
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (06) : 3785 - 3790
  • [27] Characterization of porcine p53 and its regulation by porcine Mdm2
    Lang, Yue
    Yu, Cuilian
    Tang, Jun
    Li, Gebin
    Bai, Rulan
    GENE, 2020, 748
  • [28] AMPLIFICATION OF THE MDM2 GENE IN HUMAN BREAST-CANCER AND ITS ASSOCIATION WITH MDM2 AND P53 PROTEIN STATUS
    MCCANN, AH
    KIRLEY, A
    CARNEY, DN
    CORBALLY, N
    MAGEE, HM
    KEATING, G
    DERVAN, PA
    BRITISH JOURNAL OF CANCER, 1995, 71 (05) : 981 - 985
  • [29] MDM2 Oncogene Copy Number Alterations in Chronic Lymphocytic Leukemia
    Sookaromdee, Pathum
    Wiwanitkit, Viroj
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (03) : 220 - 220
  • [30] Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers
    Battaglin, F.
    Xiu, J.
    Baca, Y.
    Shields, A. F.
    Goldberg, R. M.
    Puccini, A.
    Tokunaga, R.
    Arai, H.
    Wang, J.
    Kawanishi, N.
    Seeber, A.
    Astaturov, I.
    Lockhart, A. C.
    Zhang, W.
    Marshall, J. L.
    Korn, W. M.
    Lenz, H. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1100 - S1100